In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump's tariffs taking effect on dozens of countries ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Recent health news highlights include Kenvue cutting its sales forecast amid strategic changes, Eli Lilly raising its profit ...

The S&P 500 slipped 0.3 percent after briefly climbing to the edge of its record earlier in the morning. The Dow Jones ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...